Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi has officially discontinued development of its eczema drug amlitelimab, marking a significant shift in its pipeline strategy.
2 independently checked trend briefs about this subject, newest first.
headlinez.news detected 2 source-qualified news clusters connected to Pharma between June 23, 2026 and July 24, 2026. They span 1 newsroom category and average 6.5 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
Sanofi has officially discontinued development of its eczema drug amlitelimab, marking a significant shift in its pipeline strategy.
Gene therapy pioneer Sangamo Therapeutics files for bankruptcy, with Lilly and Astellas racing to acquire its assets